Mapi Pharma has enrolled the first patient in a multinational Phase I/II study of its once-monthly injectable cariprazine for schizophrenia and bipolar disorder, initiating dose-finding, safety, and preliminary efficacy work on a long-acting depot version of a widely used oral antipsychotic. An upfront payment from an undisclosed large pharmaceutical partner backs the program. It includes a defined go/no-go option to advance into Phase III under a commercial agreement now being negotiated.
The core move is a life-cycle extension of an established molecule into the long-acting injectable segment, where adherence advantages have shifted prescribing in schizophrenia maintenance and are gaining ground in bipolar disorder. Mapi’s formulation uses its proprietary depot technology and is initially positioned as a monthly regimen. The company has already built dedicated production capacity for the product, a notable pre-investment in aseptic manufacturing and fill-finish that is often a gating factor for depot programs. The Phase I/II study is starting in Israel, with plans to expand to additional countries, indicating an intention to generate a data package suitable for broad regulatory pathways.
Strategically, this is an attempt to open a new lane in a crowded LAI antipsychotic market by converting a molecule with significant oral penetration into an injection-based maintenance option. The undisclosed partner’s option structure preserves flexibility while it evaluates early pharmacokinetics, dose proportionality, and tolerability—key risks when translating an orally dosed agent with long-lived metabolites into a depot profile. Mapi’s choice to commit manufacturing resources ahead of pivotal data suggests confidence in its platform and a bid to de-risk supply for a potential rapid scale-up if the option is exercised. It also aligns with the company’s broader depot portfolio and experience advancing another long-acting product to FDA review, signaling an operational play as much as a clinical one.
If successful, the program could alter the dynamics for sites and sponsors involved in psychiatric trials. Sites will need capabilities for injection administration, dense PK sampling, and switching protocols from oral regimens, with careful attention to initiation, overlap, and discontinuation strategies given cariprazine’s known pharmacokinetic tail. CROs and vendors should expect designs that prioritize relapse prevention endpoints, real-world adherence measures, and pragmatic monitoring of movement and metabolic adverse events, reflecting current regulatory expectations for LAIs. For payers and health systems, a cariprazine LAI would enter head-to-head and formulary negotiations against entrenched monthly and extended-interval competitors, making differentiation on dosing flexibility, initiation logistics, and discontinuation management as necessary as efficacy.
The near-term watchlist is narrow but consequential. Detailed Phase I/II parameters—route of administration, oral lead-in and overlap requirements, PK targets relative to oral exposure, and early switching data from stable patients—will determine whether a Phase III relapse-prevention trial is feasible on an efficient timeline. Any indication that the regimen can support dosing intervals beyond monthly, which Mapi’s IP claims contemplate, would be strategically meaningful but would require robust exposure-response evidence and careful safety surveillance. Clarity on the identity and commitment level of the pharmaceutical partner will signal how aggressively the program will be resourced and how global the pivotal footprint could be. Ultimately, the program’s viability hinges on demonstrating an operationally clean initiation and maintenance experience that can compete against established LAIs while satisfying regulators’ growing emphasis on real-world adherence outcomes and consistent performance across diverse patient populations.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
